Advertisement

Discovery of a Novel Potent Inhibitor of HIV Infection

  • J. P. Bader
  • J. B. McMahon
  • R. J. Schultz
  • V. L. Narayanan
  • J. B. Pierce
  • W. A. Harrison
  • O. S. Weislow
  • C. F. Midelfort
  • M. R. Boyd
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

A number of agents active against the human immunodeficiency virus (HIV) currently are under consideration for clinical use in AIDS. Nonetheless, the only drugs exhibiting unequivocal clinical efficacy are those which inhibit the activity of viral reverse transcriptase, specifically certain dideoxynucleosides including azidothymidine (AZT)(1), dideoxycytidine (DDC)(2), and dideoxyinosine (3). The failure to effect a complete cure of the disease with dideoxynucleosides, the toxicities associated with longterm treatments with these compounds (2,4), and the occurrence of AZT-resistant mutants (5), are considerations which necessitate the discovery and development of new drugs effective against AIDS.

Keywords

Human Immunodeficiency Virus Thionyl Chloride Human Immunodeficiency Virus Protease Chlorobenzoic Acid Human Immunodeficiency Virus Reverse Transcriptase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yarchoan R, Kelecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW, Shearer GM, Fischi MA, Mitsuya H, Gallo RC, Collins JM, Bolognesi DP, Myers CE, Broder, S. Administration of 3’ -azido-3’ -deoxythymidine, an inhibitor of HTLVIII/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1: 575–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, Mitsuya H, Pluda JM, Lawley TJ, Leuther M, Safai B, Collins JM, Myers CE, Broder S. Phase I studies of 2’,3’ -dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988; 1: 76–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Ahluwalia G, Conney DA, Mitsuya H, Fridland A, Flora KP, Hao Z, Dalal M, Broder S, Johns DG. Initial studies on the cellular pharmacology of 2’,3’ -dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987; 36: 3797–800.PubMedCrossRefGoogle Scholar
  4. 4.
    Richman DD, Fischi MA, Grieco MH, Gottlieb MS, Jackson GG, Durack DT, Lehrman-Nusinoff S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 192–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989; 243: 1731–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Boyd MR. Strategies for the identification of new agents for the treatment of AIDS: A national program to facilitate the discovery and preclinical development of new drug candidates for clinical evaluation. In Devita VT Jr, Hellman S, Rosenberg SA, eds. AIDS Etiology, Diagnosis, Treatment and Prevention. Philadelphia: Lipencott 1988, 305–317.Google Scholar
  7. 7.
    Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH, Boyd MR. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 1989; 81: 577–86.PubMedCrossRefGoogle Scholar
  8. 8.
    Bader J, McMahon J, Schultz R, Narayanan V, Boyd M. Oxathiin carboxanilide: A novel potent inhibitor of HIV reproduction. Third Int Conf on Antiviral Research, April 22–27, 1990.Google Scholar
  9. 9.
    Midelfort F, Schultz R, Narayanan V, Weislow O, McMahon J, Bader J, Boyd M. AIDS antiviral activity of oxathiin benzoic acid ester (NSC 615985). Sixth Int Conf on AIDS, San Francisco, June 243, 20–24, 1990.Google Scholar
  10. 10.
    Harrison WA, Kulka M, Thiara DS, von Schemeling B. US Patent 3, 249, 499, 1966.Google Scholar
  11. 11.
    Bader JP, McMahon JB, Schultz RJ, Narayanan VL, Pierce JB, Harrison WA, Weislow OS, Midelfort CF, Stinson SF, Boyd MR. Oxathiin carboxanilide, A potent inhibitor of human immunodeficiency virus reproduction. Submitted for publication.Google Scholar
  12. 12.
    Bader JP. Transformation by Rous sarcoma virus: a requirement for DNA synthesis. Science 1965; 149: 757–758.PubMedCrossRefGoogle Scholar
  13. 13.
    Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimada T, Stein CA, Mitsuya H, Wong-Staal F, Cohen JS, Broder S. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA 1989; 86: 4244–8.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • J. P. Bader
    • 1
  • J. B. McMahon
    • 1
  • R. J. Schultz
    • 1
  • V. L. Narayanan
    • 1
  • J. B. Pierce
    • 2
  • W. A. Harrison
    • 3
  • O. S. Weislow
    • 4
  • C. F. Midelfort
    • 1
  • M. R. Boyd
    • 1
  1. 1.Developmental Therapeutics ProgramNational Cancer InstituteBethesdaUSA
  2. 2.Uniroyal Chemical Company, Inc.MiddleburyUSA
  3. 3.Uniroyal Chemical Ltd.GuelphCanada
  4. 4.Frederick Cancer Research and Development CenterProgram Resources, Inc.FrederickUSA

Personalised recommendations